CRNX Stock Analysis: Buy, Sell, or Hold?
CRNX - Crinetics Pharmaceuticals, Inc.
$33.67
-2.64 (-7.27%)
▼
5d:
-5.34%
30d:
-23.02%
90d:
-31.1%
HOLD
LOW Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation
CRNX is down 9.3% this week, but smart money is accumulating calls. Top strike: $30 2026-06-18 with 45 OI. Call ratio: 73% View Scanner →
Strength: 7.0/10
Get Alerted When CRNX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CRNX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CRNX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CRNX is currently trading at $33.67, which is considered oversold relative to its 30-day fair value range of $35.73 to $42.42.
Technical Outlook: Technically, CRNX is in a downtrend. The price is currently testing key support at $33.40. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.3% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $83.50 (+148.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CRNX is in a downtrend. The price is currently testing key support at $33.40. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.3% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $83.50 (+148.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$35.73 -
$42.42
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.3%)
- BULLISH: Trading 148.0% below Wall St target ($83.50)
- CAUTION: Recommendation downgraded due to -5.3% 5-day decline
Fair Price Analysis
30-Day Fair Range
$35.73 -
$42.42
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$33.40
Resistance Level
$38.49
Current Trend
Downtrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.25
Wall Street Target
$83.50
(+148.0%)
Revenue Growth (YoY)
158.4%
Share & Embed Analysis
Last updated: March 30, 2026 8:52 AM ET
Data refreshes hourly during market hours. Next update: 9:52 AM
Data refreshes hourly during market hours. Next update: 9:52 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRNX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Richard Scott Struthers
SELL
21981 shares
2026-03-16
Stephen F Betz
SELL
10612 shares
2026-03-16
Jeff E Knight
SELL
9911 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 54 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 53 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 53 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$119 | 60 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 42 HOLD |
